Identification and evaluation of helvolic acid as an antibacterial compound against Neisseria gonorrhoeae

View at publisher Summarise with VIRAT
Authors: Sota Honma, Aoi Kimishima, Hidehito Matsui, Atsuka Nishitomi, Sota Negami, Taichi Kamo, Yukiko Ujie, Paul Wasuwanich, Masako Honsho, Hiroki Kojima, Toshiyuki Tokiwa, Akihiro Sugawara
+1 more Yukihiro Asami
Cited by: 0
References: 27

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Neisseria gonorrhoeae infection causes significant morbidity and can have serious long-term impacts on reproductive and neonatal health. Global rates of N. gonorrhoeae infection have been increasing steadily over the past 20 years, and rates of resistance to key antibiotics have also continued to increase. Given the situation, the United States Centers for Disease Control and Prevention (CDC) identified drug-resistant N. gonorrhoeae as an urgent threat to public health. In this study, we aimed to discover antibacterial compounds against N. gonorrhoeae from an in-house fungal culture broth library. After the screening program, we identified helvolic acid (1), produced by Aspergillus unilateralis FKI-6908 strain, as a target antibacterial compound. Compound 1 demonstrated great antibacterial activity even against drug-resistant N. gonorrhoeae clinical isolate strains, suggesting its potential for the treatment of N. gonorrhoeae infections.

Fields of Study & Subjects

Microbial Natural Products and Biosynthesis Microbial Metabolism and Applications Bioactive natural compounds

Publication details

Journal / source
Bioscience Biotechnology and Biochemistry
Volume
90
Issue
6
Pages
780–784
Publication date
24 March 2026
Language
EN